Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
Currently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3053 |
| _version_ | 1797862565528731648 |
|---|---|
| author | E. L. Nasonov T. V. Popkova A. M. Lila |
| author_facet | E. L. Nasonov T. V. Popkova A. M. Lila |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Currently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and plasma cells are considered a promising direction. pharmacotherapy of these diseases. of particular interest is belimumab (BLM), a human monoclonal antibody (mAb) (IgG1λ) to BAFF (B cell-activating factor belonging to the TNF family), which is the first “targeted” biological drug specially developed for the treatment of systemic lupus erythematosus (SLE). The efficacy and safety of BLM in SLE in adults and children, including lupus nephritis, in combination therapy with rituximab, steroid-sparing effect, the ability to prevent irreversible damage to internal organs dictate the need for its wider application in clinical practice. |
| first_indexed | 2024-04-09T22:21:26Z |
| format | Article |
| id | doaj.art-24e00cc443c4435c8c8369be8f87ff34 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:21:26Z |
| publishDate | 2021-09-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-24e00cc443c4435c8c8369be8f87ff342023-03-22T13:45:57ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-09-0159436738310.47360/1995-4484-2021-367-3832726Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practiceE. L. Nasonov0T. V. Popkova1A. M. Lila2V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationCurrently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and plasma cells are considered a promising direction. pharmacotherapy of these diseases. of particular interest is belimumab (BLM), a human monoclonal antibody (mAb) (IgG1λ) to BAFF (B cell-activating factor belonging to the TNF family), which is the first “targeted” biological drug specially developed for the treatment of systemic lupus erythematosus (SLE). The efficacy and safety of BLM in SLE in adults and children, including lupus nephritis, in combination therapy with rituximab, steroid-sparing effect, the ability to prevent irreversible damage to internal organs dictate the need for its wider application in clinical practice.https://rsp.mediar-press.net/rsp/article/view/3053systemic lupus erythematosusbelimumabrituximab |
| spellingShingle | E. L. Nasonov T. V. Popkova A. M. Lila Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice Научно-практическая ревматология systemic lupus erythematosus belimumab rituximab |
| title | Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice |
| title_full | Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice |
| title_fullStr | Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice |
| title_full_unstemmed | Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice |
| title_short | Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice |
| title_sort | belimumab in the treatment of systemic lupus erythematosus 20 years of basic research 10 years of clinical practice |
| topic | systemic lupus erythematosus belimumab rituximab |
| url | https://rsp.mediar-press.net/rsp/article/view/3053 |
| work_keys_str_mv | AT elnasonov belimumabinthetreatmentofsystemiclupuserythematosus20yearsofbasicresearch10yearsofclinicalpractice AT tvpopkova belimumabinthetreatmentofsystemiclupuserythematosus20yearsofbasicresearch10yearsofclinicalpractice AT amlila belimumabinthetreatmentofsystemiclupuserythematosus20yearsofbasicresearch10yearsofclinicalpractice |